Toward the elimination of lymphatic filariasis by 2020: Treatment update and impact assessment for the endgame

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 7, 2013, Pages 723-731

  Rebollo, Maria P ^a   Bockarie, Moses J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

endgame; London declaration; lymphatic filariasis; mass drug administration; monitoring and evaluation; neglected tropical diseases; preventive chemotherapy; transmission assessment surveys; xenomonitoring

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; MOXIDECTIN;

BIOLOGICAL MONITORING; DISEASE CARRIER; DISEASE SURVEILLANCE; DRUG EFFICACY; GEOGRAPHIC DISTRIBUTION; GEOGRAPHIC MAPPING; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH SURVEY; HELMINTHIASIS; HOST PARASITE INTERACTION; HUMAN; HYDROCELE; INFECTION CONTROL; LOIASIS; LYMPHATIC FILARIASIS; LYMPHEDEMA; MATHEMATICAL MODEL; MOLECULAR XENOMONITORING; NONHUMAN; ONCHOCERCIASIS; PARASITE CLEARANCE; PARASITE IDENTIFICATION; PREVALENCE; PUBLIC HEALTH SERVICE; REVIEW;

EID: 84880915415     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.811841     Document Type: Review

References (58)

1. WHO. Sustaining the drive to overcome the global impact of neglected tropical diseases: Second WHO report on neglected diseases (WHO/HTM/NTD/2013.1). (2013
2. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl. Trop. Dis. 4(6), e708 (2010
3. Ramaiah KD, Ramu K, Guyatt H, Kumar KN, Pani SP. Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of Tamil Nadu, south India. Trop. Med. Int. Health 3(2), 108-115 (1998
4. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 376(9747), 1175-1185 (2010
5. Bockarie MJ, Taylor MJ, Gyapong JO. Current practices in the management of lymphatic filariasis. Expert Rev. Anti. Infect. Ther. 7(5), 595-605 (2009
6. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the Global Programme to Eliminate Lymphatic Filariasis. Expert Opin. Pharmacother. 6(2), 179-200 (2005
7. WHO. Managing morbidity and preventing disability in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement. Wkly. Epidemiol. Rec. 86(51-52), 581-585 (2011
8. Molyneux DH. 10 years of success in addressing lymphatic filariasis. Lancet 373(9663), 529-530 (2009
9. Molyneux DH. Combating the 'other diseases' of MDG 6: Changing the paradigm to achieve equity and poverty reduction? Trans. R. Soc. Trop. Med. Hyg. 102(6), 509-519 (2008
10. Molyneux DH, Hotez PJ, Fenwick A, Newman RD, Greenwood B, Sachs J. Neglected tropical diseases and the Global Fund. Lancet 373(9660), 296-297 (2009
11. WHO. Accelerated work to overcome the global impact of neglected tropical diseases: A roapmap for implementation (WHO/HTM/NTD/2012.1). (2012
12. WHO. Global programme to eliminate lymphatic filariasis: Progress report, 2011. Wkly. Epidemiol. Rec. 87(37), 346-356 (2012
13. Graves PM, Makita L, Susapu M et al. Lymphatic filariasis in Papua New Guinea: Distribution at district level and impact of mass drug administration, 1980 to 2011. Parasit. Vectors 6, 7 (2013
14. Stolk WA, ten Bosch QA, de Vlas SJ, Fischer PU, Weil GJ, Goldman AS. Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis. PLoS Negl. Trop. Dis. 7(1), e1984 (2013
15. Taylor M, Mediannikov O, Raoult D, Greub G. Endosymbiotic bacteria associated with nematodes, ticks and amoebae. FEMS Immunol. Med. Microbiol. 64(1), 21-31 (2012
16. Taylor MJ, Voronin D, Johnston KL, Ford L. Wolbachia filarial interactions. Cell. Microbiol. doi:10.1111/cmi.12084 (2012) (Epub ahead of print
17. Tamarozzi F, Tendongfor N, Enyong PA et al. Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis. Parasit. Vectors 5, 53 (2012
18. Slatko BE, Taylor MJ, Foster JM. The Wolbachia endosymbiont as an anti-filarial nematode target. Symbiosis 51(1), 55-65 (2010
19. Debrah AY, Mand S, Specht S et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog. 2(9), e92 (2006
20. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: A double-blind, randomised placebo-controlled trial. Lancet 365(9477), 2116-2121 (2005
21. Debrah AY, Mand S, Marfo-Debrekyei Y et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop. Med. Int. Health 12(12), 1433-1441 (2007
22. Debrah AY, Mand S, Marfo-Debrekyei Y et al. Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline. Am. J. Trop. Med. Hyg. 80(6), 956-963 (2009
23. Mand S, Debrah AY, Klarmann U et al. Doxycycline improves filarial lymphedema independent of active filarial infection: A randomized controlled trial. Clin. Infect. Dis. 55(5), 621-630 (2012
24. Wanji S, Tendongfor N, Nji T et al. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasit. Vectors 2(1), 39 (2009
25. Townson S, Ramirez B, Fakorede F, Mouries MA, Nwaka S. Challenges in drug discovery for novel antifilarials. Expert Opin. Drug Discov. 2(s1), S63-S73 (2007
26. Yajima A, Mikhailov A, Mbabazi PS et al. Preventive Chemotherapy and Transmission Control (PCT) databank: A tool for planning, implementation and monitoring of integrated preventive chemotherapy for control of neglected tropical diseases. Trans. R. Soc. Trop. Med. Hyg. 106(4), 215-222 (2012
27. WHO. Monitoring and epidemiological assessment of mass drug administration: A manual for national elimination programmes (WHO/HTM/NTD/ PCT/2011.4). (2011
28. WHO. Transmission assessment surveys in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement. Wkly Epidemiol. Rec. 87(48), 478-482 (2012
29. Molyneux DH. Filaria control and elimination: Diagnostic, monitoring and surveillance needs. Trans. R. Soc. Trop. Med. Hyg. 103(4), 338-341 (2009
30. Baker MC, Mathieu E, Fleming FM et al. Mapping, monitoring, and surveillance of neglected tropical diseases: Towards a policy framework. Lancet 375(9710), 231-238 (2010
31. Kelly-Hope LA, Thomas BC, Bockarie MJ, Molyneux DH. Lymphatic filariasis in the Democratic Republic of Congo; micro-stratification overlap mapping (MOM) as a prerequisite for control and surveillance. Parasit. Vectors 4, 178 (2011
32. Zouré; HG, Wanji S, Noma M et al. The geographic distribution of Loa loa in Africa: Results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl. Trop. Dis. 5(6), e1210 (2011
33. WHO Global programme to eliminate lymphatic filariasis: Progress report 2000-2009 and strategic plan 2010-2020 (WHO/HTM/NTD/PCT/2010.6). (2010
34. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull. World Health Organ. 75(6), 491-503 (1997
35. WHO. Progress toward elimination of lymphatic filariasis -Togo, 2000-2009. MMWR. Morb. Mortal. Wkly. Rep. 60(29), 989-991 (2011
36. Montresor A, Gabrielli AF, Chitsulo L et al. Preventive chemotherapy and the fight against neglected tropical diseases. Expert Rev. Anti. Infect. Ther. 10(2), 237-242 (2012
37. Filariasis elimination, Zanzibar. Wkly. Epidemiol. Rec. 76(51-52), 406-408 (2001
38. Meyrowitsch DW, Simonsen PE, Magesa SM. Long-Term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: Follow-up at 10 years after treatment. Trans. R. Soc. Trop. Med. Hyg. 98(11), 627-634 (2004
39. Noordin R, Muhi J, Md Idris Z, Arifin N, Kiyu A. Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia. Trop. Biomed. 29(1), 191-196 (2012
40. Weil GJ, Ramzy RM. Diagnostic tools for filariasis elimination programs. Trends Parasitol. 23(2), 78-82 (2007
41. Swaminathan S, Perumal V, Adinarayanan S, Kaliannagounder K, Rengachari R, Purushothaman J. Epidemiological assessment of eight rounds of mass drug administration for lymphatic filariasis in India: Implications for monitoring and evaluation. PLoS Negl. Trop. Dis. 6(11), e1926 (2012
42. Ramaiah KD, Vanamail P. Surveillance of lymphatic filariasis after stopping ten years of mass drug administration in rural communities in south India. Trans. R. Soc. Trop. Med. Hyg. 107(5), 293-300 (2013
43. Gass K, Beau de Rochars MV, Boakye D et al. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl. Trop. Dis. 6(1), e1479 (2012
44. Weil GJ, Curtis KC, Fischer PU et al. A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop. 120(SUPPL.. 1), S19-S22 (2011
45. Erickson SM, Fischer K, Weil GJ, Christensen BM, Fischer PU. Distribution of Brugia malayi larvae and DNA in vector and non-vector mosquitoes: Implications for molecular diagnostics. Parasit. Vectors 2(1), 56 (2009
46. Weil GJ, Kastens W, Susapu M et al. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl. Trop. Dis. 2(12), e344 (2008
47. Ramzy RM, El Setouhy M, Helmy H et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: A comprehensive assessment. Lancet 367(9515), 992-999 (2006
48. Helmy H, Weil GJ, Ellethy AS, Ahmed ES, Setouhy ME, Ramzy RM. Bancroftian filariasis: Effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans. R. Soc. Trop. Med. Hyg. 100(7), 656-662 (2006
49. Weil G, Curtis K, Fakoli L et al. Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood. Am. J. Trop. Med. Hyg. (2013) (In Press
50. Laney SJ, Ramzy RM, Helmy HH et al. Detection of Wuchereria bancrofti L3 larvae in mosquitoes: A reverse transcriptase PCR assay evaluating infection and infectivity. PLoS Negl. Trop. Dis. 4(2), e602 (2010
51. Bockarie MJ. Molecular xenomonitoring of lymphatic filariasis. Am. J. Trop. Med. Hyg. 77(4), 591-592 (2007
52. Bockarie MJ, Fischer P, Williams SA et al. Application of a polymerase chain reaction-ELISA to detect Wuchereria bancrofti in pools of wild-caught Anopheles punctulatus in a filariasis control area in Papua New Guinea. Am. J. Trop. Med. Hyg. 62(3), 363-367 (2000
53. Ramzy RM, Farid HA, Kamal IH et al. A polymerase chain reaction-based assay for detection of Wuchereria bancrofti in human blood and Culex pipiens. Trans. R. Soc. Trop. Med. Hyg. 91(2), 156-160 (1997
54. Bockarie MJ, Pedersen EM, White GB, Michael E. Role of vector control in the global program to eliminate lymphatic filariasis. Annu. Rev. Entomol. 54, 469-487 (2009
55. Gambhir M, Bockarie M, Tisch D et al. Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biol. 8, 22 (2010
56. Southgate BA, Bryan JH. Factors affecting transmission of Wuchereria bancrofti by anopheline mosquitoes. 4. Facilitation, limitation, proportionality and their epidemiological significance. Trans. R. Soc. Trop. Med. Hyg. 86(5), 523-530 (1992
57. Fischer P, Erickson SM, Fischer K et al. Persistence of Brugia malayi DNA in vector and non-vector mosquitoes: Implications for xenomonitoring and transmission monitoring of lymphatic filariasis. Am. J. Trop. Med. Hyg. 76(3), 502-507 (2007
58. Slater H, Michael E. Predicting the current and future potential distributions of lymphatic filariasis in Africa using maximum entropy ecological niche modelling. PLoS One 7(2), e32202 (2012